VCA Stocks

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has closed a $20 million Series D equity financing.  Collegium is focused on building a portfolio of pain products that incorporate its patent protected DETERx formulation platform that provides for sustained release and tamper resistance. The Company also through its subsidiary, Onset Therapeutics develops and commercializes products for skin and skin related disorders using its novel DELEVO Foam Technology.